Leow, Benjamin C. S.
Kok, Chung H.
Yeung, David T.
Hughes, Timothy P.
White, Deborah L.
Eadie, Laura N.
Funding for this research was provided by:
Novartis Australia
Bristol-Myers Squibb
Article History
Received: 17 May 2023
Accepted: 8 August 2023
First Online: 11 August 2023
Competing interests
: B.L., C.H.K., and L.N.E. have no conflicts of interest to declare. T.P.H. and D.T.Y. receive research funding from Novartis and Bristol Myers Squibb. T.P.H. is on the advisory boards of Novartis, Takeda, Terns and Enliven. D.T.Y. is on the advisory boards of Novartis, Takeda, Amgen and Pfizer. D.L.W. receives honoraria and research funding from Bristol-Myers Squibb and Novartis, and honoraria from Amgen and Pfizer. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.